A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors

被引:32
|
作者
Lavigne, Jill E. [1 ]
Heckler, Charles [2 ]
Mathews, Jennifer L. [1 ]
Palesh, Oxana [3 ]
Kirshner, Jeffrey J. [4 ]
Lord, Raymond [4 ]
Jacobs, Andrew [4 ]
Amos, Eric [1 ]
Morrow, Gary R. [2 ]
Mustian, Karen [2 ]
机构
[1] St John Fisher Coll, Wegmans Sch Pharm, Rochester, NY 14618 USA
[2] Univ Rochester, Med Ctr, Dept Radiat Oncol, James P Wilmot Canc Ctr, Rochester, NY 14642 USA
[3] Stanford Univ, Sch Med, Dept Psychiat, Palo Alto, CA 94304 USA
[4] Univ Rochester, Med Ctr, James P Wilmot Canc Ctr, Community Clin Oncol Base, Rochester, NY 14642 USA
关键词
Gabapentin; Neurontin; Anti-epileptics; Breast; Cancer; Anxiety; Randomized controlled trial; Cancer survivorship; PRIMARY-CARE; FOLLOW-UP; PAIN; EFFICACY; MANAGEMENT; DISORDER; BENZODIAZEPINES; MULTICENTER; PREGABALIN; SURGERY;
D O I
10.1007/s10549-012-2251-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gabapentin is used for the treatment of hot flashes and neuropathic pain in breast cancer survivors, and is commonly used off-label for the treatment of anxiety. Yet, clinical trial evidence to support the use of gabapentin for anxiety symptoms is lacking. In a randomized, double-blinded controlled trial we compared 300 mg gabapentin versus 900 mg gabapentin versus placebo. Subjects were 420 breast cancer patients who had completed all chemotherapy cycles. Anxiety traits and current (state) anxiety were measured using the Speilberger Strait-Trait Anxiety Inventory at baseline, 4 and 8 weeks. Pain was measured at baseline using a 10-point scale. Analyses included analysis of covariance and ordinary least squares regression. At 4 weeks, state anxiety change scores were significantly better for gabapentin 300 and 900 mg (p = 0.005) compared to placebo. The magnitude of improvement was proportional to baseline state anxiety. At 8 weeks, the anxiolytic effects of gabapentin compared to placebo persisted (p < 0.005). We found no significant interactions. The lower dose (300 mg) was associated with the best treatment outcomes for all patients except those with the highest baseline anxiety. Given its similar pharmacology, efficacy in the treatment of hot flashes, and low cost, gabapentin may provide a low cost and parsimonious alternative treatment choice for breast cancer survivors presenting in primary care practices with anxiety symptoms. Gabapentin is effective for hot flashes, and, therefore, may provide therapeutic benefit for both anxiety and hot flashes at a generic drug price. For patients reluctant to take a controlled substance, such as a benzodiazepine, gabapentin may offer an alternative therapy. Similarly, patients with a history of substance use may benefit from gabapentin without risk of addiction or abuse. For cancer survivors experiencing both hot flashes and anxiety, gabapentin may provide a single effective treatment for both and is an alternative therapy for anxiety for patients unwilling to take a benzodiazepine or those with a history of substance use.
引用
收藏
页码:479 / 486
页数:8
相关论文
共 50 条
  • [41] Dietary Treatment of Crohn's Disease: A Randomized, Placebo-Controlled, Double-Blinded Clinical Trial
    Mutlu, Ece
    Mikolaitis, Susan
    Sedghi, Shahriar
    Chakradeo, Prachi S.
    Engen, Phillip
    Chlipala, George
    Green, Stefan
    Keshavarzian, Ali
    GASTROENTEROLOGY, 2016, 150 (04) : S778 - S778
  • [42] Intravenous dexamethasone as an adjunct to improve labor analgesia: A randomized, double-blinded, placebo controlled clinical trial
    Dube, Pratibha
    Mitra, Sukanya
    Singh, Jasveer
    Saroa, Richa
    Mehra, Reeti
    JOURNAL OF CLINICAL ANESTHESIA, 2017, 43 : 6 - 10
  • [43] Multimodal Pain Management for Cesarean Delivery: A Double-Blinded, Placebo-Controlled, Randomized Clinical Trial
    Hadley, Emily E.
    Monsivais, Luis
    Pacheco, Lucia
    Babazade, Rovnat
    Chiossi, Giuseppe
    Ramirez, Yara
    Ellis, Viviana
    Simon, Michelle
    Saade, George R.
    Costantine, Maged
    AMERICAN JOURNAL OF PERINATOLOGY, 2019, 36 (11) : 1097 - 1105
  • [44] Counterforce bracing of lateral epicondylitis: a prospective, randomized, double-blinded, placebo-controlled clinical trial
    Kroslak, Martin
    Pirapakaran, Kajan
    Murrell, George A. C.
    JOURNAL OF SHOULDER AND ELBOW SURGERY, 2019, 28 (02) : 288 - 295
  • [45] Surgical Treatment of Lateral Epicondylitis A Prospective, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial
    Kroslak, Martin
    Murrell, George A. C.
    AMERICAN JOURNAL OF SPORTS MEDICINE, 2018, 46 (05): : 1106 - 1113
  • [46] Efficacy of Momiai in Tibia Fracture Repair: A Randomized Double-Blinded Placebo-Controlled Clinical Trial
    Sadeghi, Seyed Mohammad Hasan
    Khameneh, Seyed Mehdi Hosseini
    Khodadoost, Mahmood
    Kasnavieh, Seyed Mohammad Hosseini
    Kamalinejad, Mohammad
    Gachkar, Latif
    Rampp, Thomas
    Pasalar, Mehdi
    JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, 2020, 26 (06) : 521 - 528
  • [47] Azithromycin therapy of papillomatosis in dogs:: a prospective, randomized, double-blinded, placebo-controlled clinical trial
    Yagci, Bugrahan Bekir
    Ural, Kerem
    Ocal, Naci
    Haydardedeoglu, Ali Evren
    VETERINARY DERMATOLOGY, 2008, 19 (04) : 194 - 198
  • [48] Once daily 300 mg aspirin with compression versus compression alone in patients with chronic venous leg ulcers (ASPiVLU): A randomised, double-blinded, multicentre, placebo-controlled, clinical trial
    Weller, Carolina D.
    Martin, Catherine
    Bouguettaya, Ayoub
    Underwood, Martin
    Barker, Anna L.
    Haines, Terry
    Pouniotis, Dodie
    Wolfe, Rory
    JOURNAL OF TISSUE VIABILITY, 2021, 30 (04) : 509 - 516
  • [49] Pomegranate seed oil in women with menopausal symptoms: a prospective randomized, placebo-controlled, double-blinded trial
    Auerbach, Leo
    Rakus, Julia
    Bauer, Clemens
    Gerner, Christopher
    Ullmann, Ronald
    Wimmer, Helge
    Huber, Johannes
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2012, 19 (04): : 426 - 432
  • [50] Prospective double-blinded randomized controlled trial of Microwave versus RadioFrequency Ablation for hepatocellular carcinoma (McRFA trial)
    Chong, C. N. Chong
    Lee, Kit F.
    Cheung, Sunny Y. S.
    Chu, Clement C. M.
    Fong, Anthony K. W.
    Wong, John
    Hui, Joyce W. Y.
    Fung, Andrew K. Y.
    Lok, Hon T.
    Lo, Eugene Y. J.
    Chan, Stephen L.
    Yu, Simon C. H.
    Ng, Kelvin K. C.
    Lai, Paul B. S.
    HPB, 2020, 22 (08) : 1121 - 1127